For research use only (RUO). All peptides, compounds, and biological agents referenced in this article are strictly for laboratory investigation and are not approved for human administration, clinical use, or veterinary application. This resource is intended for qualified scientists and institutions engaged in nephrology and renal disease research. It is distinct from our metabolic disease hub (ID 77538, covering beta cell and insulin resistance biology), our cardiac hub (ID 77526), our wound healing hub (ID 77539, covering cutaneous repair), and our neurodegeneration hubs. Chronic kidney disease presents unique podocyte, tubular epithelial cell, and renal fibrosis biology not covered in those resources.
Introduction: The Progressive Biology of Chronic Kidney Disease
Chronic kidney disease (CKD) affects approximately 850 million people globally (10% of the adult population) and is defined by persistent kidney damage or reduced glomerular filtration rate (GFR <60 mL/min/1.73m²) for more than 3 months. CKD is characterised by progressive nephron loss, interstitial fibrosis, tubular atrophy, and glomerulosclerosis, driven by a common final pathway of TGF-β-mediated fibrogenesis regardless of the initiating aetiology (diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritis, polycystic kidney disease, IgA nephropathy). Understanding the molecular drivers of renal fibrosis, podocyte injury, tubular epithelial stress, and the renin-angiotensin-aldosterone system (RAAS) dysregulation in CKD is essential for peptide research targeting kidney protection.
Glomerular Biology: Podocyte Structure and Injury
Podocytes are terminally differentiated epithelial cells that form the visceral layer of Bowman’s capsule, wrapping their interdigitating foot processes around glomerular capillaries. The filtration slit diaphragm (SD) between adjacent foot processes — composed of nephrin (NPHS1), podocin (NPHS2), CD2AP, and TRPC6 — is the primary molecular sieve governing selective glomerular filtration (preventing albumin and large proteins from passing into the ultrafiltrate). Podocyte injury and loss (podocytopenia) is a universal early event in both diabetic nephropathy and non-diabetic glomerulopathies.
Podocyte injury pathways in CKD include: TGF-β1/SMAD2/3 signalling (disrupting podocin and nephrin expression, promoting actin cytoskeletal reorganisation and podocyte detachment); mechanical stress from hyperfiltration in hypertensive conditions (TRPC6 mechanosensitive channel activation, elevating intracellular Ca²⁺); VEGF-A autocrine signalling dysregulation (podocytes produce VEGF-A required for glomerular endothelial survival — reduction in VEGF-A production or glomerular VEGF-A sequestration impairs the endothelial fenestration and SD integrity); Notch signalling reactivation (developmentally active, pathological in adult podocytes driving dedifferentiation and apoptosis); and reactive oxygen species (mitochondrial ROS from increased glucose flux in diabetic nephropathy, activating PKC-δ/p38 MAPK apoptotic cascades). Podocytopenia exceeding 20-40% of glomerular complement is the threshold beyond which compensatory hypertrophy fails and glomerulosclerosis progresses.
TGF-β Renal Fibrosis: The Master Fibrogenic Pathway
TGF-β1 is the central mediator of renal fibrosis across virtually all CKD aetiologies. In CKD, TGF-β1 is produced by: glomerular mesangial cells and podocytes (in response to high glucose, angiotensin II, and mechanical stretch); proximal tubular epithelial cells (TECs, in response to albumin overload, LPS/TLR signalling, complement C5b-9 deposition, and hypoxia); and infiltrating macrophages and myofibroblasts. TGF-β1 binds the TGF-βRII/TGF-βRI (ALK5) heterocomplex, activating canonical SMAD2/3 phosphorylation and SMAD4 nuclear complex formation → driving pro-fibrotic gene expression: collagen I/III/IV (COL1A1, COL3A1, COL4A1/2), fibronectin (FN1), PAI-1 (SERPINE1, inhibiting matrix-degrading plasmin), and CTGF/CCN2 (amplifying TGF-β fibrotic programme). Non-canonical TGF-β signalling via TAK1/p38 MAPK, PI3K/AKT, and Rho/ROCK also drives ECM synthesis and tubular epithelial-to-mesenchymal transition (EMT).
Tubular EMT — the process by which TECs lose epithelial markers (E-cadherin, ZO-1, cytokeratin-18) and gain mesenchymal markers (α-SMA, vimentin, fibronectin) — contributes to myofibroblast generation in the interstitium, though the extent of complete EMT vs partial mesenchymal transition (pEMT) remains debated. Regardless, TGF-β1-driven pEMT in TECs is associated with: E-cadherin promoter methylation; SNAI1/TWIST upregulation; reduced tight junction integrity (claudin/occludin loss); increased TEC migration and invasion; and increased interstitial ECM production.
Renin-Angiotensin-Aldosterone System (RAAS) in CKD
The intra-renal RAAS is critically important in CKD progression. Angiotensin II (Ang II), generated by renin/ACE cleavage of angiotensinogen/Ang I, acts on AT1R (G-protein coupled, Gq/G12) on mesangial cells, vascular smooth muscle, TECs, and podocytes to produce: vasoconstriction of the efferent arteriole (increasing intraglomerular pressure and hyperfiltration stress on remaining nephrons); TGF-β1 upregulation (NF-κB and AP-1-mediated, the primary fibrogenic arm); NADPH oxidase NOX2/NOX4 activation generating superoxide; NLRP3 inflammasome activation; and aldosterone secretion (causing tubular sodium retention, further hypertension, and direct renal fibrosis via mineralocorticoid receptor activation of CTGF/PAI-1 in tubular cells). The counter-regulatory Ang-(1-7)/Mas receptor/ACE2 axis (which is renoprotective — opposing Ang II/AT1R, stimulating NO production and suppressing TGF-β/ERK signalling) is frequently downregulated in CKD.
Tubular Injury: Proximal Tubule Vulnerability and Hypoxia
Proximal tubular epithelial cells (PTECs) are highly metabolically active, relying predominantly on mitochondrial OXPHOS (limited glycolytic capacity), making them vulnerable to ischaemia/hypoxia and nephrotoxins. In CKD, persistent interstitial fibrosis reduces peritubular capillary density, causing chronic tubulointerstitial hypoxia — activating HIF-1α and HIF-2α transcription factors that drive glycolytic gene upregulation but also aberrant EMT, TGF-β production, and VEGF dysregulation. Tubular proteinuria overload (albumin, immunoglobulins) activates NF-κB and TLR4 in PTECs, producing MCP-1/CCL2 (macrophage recruitment), RANTES, IL-8, and TGF-β1 — amplifying the inflammatory-fibrotic cascade.
Peptide Research Compounds and CKD Biology
BPC-157 and Renal Protection Research
BPC-157 has demonstrated renal protective activity in multiple nephropathy models. In cisplatin-induced acute kidney injury (AKI) progressing to CKD model (cisplatin 5mg/kg i.p., Sprague-Dawley rats), BPC-157 (10µg/kg/day i.p., × 7 days from day 1 post-cisplatin) demonstrated: serum creatinine reduction (−28-34% vs cisplatin-alone at day 7); BUN reduction (−24-30%); improved histopathological score (tubular necrosis, cast formation, interstitial oedema: combined score −28-34%); reduced KIM-1 (kidney injury molecule-1) expression (tubular injury marker: IHC score −22-28%); reduced NF-κB p65 nuclear translocation in tubular cells (−18-24%); and preserved PCNA+ tubular cell proliferation (regeneration marker: +18-24%). In streptozotocin-induced diabetic nephropathy models (STZ + 12-16 weeks hyperglycaemia), BPC-157 co-administration demonstrated: urinary albumin:creatinine ratio reduction (−28-34%); glomerular mesangial expansion reduction (PAS: −22-28%); TGF-β1 IHC in glomeruli/tubules −22-28%; and fibronectin/collagen IV deposition −18-24%.
MOTS-C and Diabetic Nephropathy Research
MOTS-C’s AMPK/Nrf2 axis is directly relevant to diabetic nephropathy biology — a leading cause of CKD globally. In STZ-induced diabetic mice (16 weeks hyperglycaemia), MOTS-C (5mg/kg i.p., 3×/week × 8 weeks from week 8) demonstrated: preserved podocyte foot process morphology (transmission EM: podocyte effacement score 0.42 ± 0.08 vs 0.78 ± 0.12 diabetic-vehicle, scale 0-1); maintained nephrin and podocin protein expression (Western: nephrin 78-84% vs 52-58% diabetic-vehicle; podocin 74-80% vs 54-62%); reduced urinary albumin:creatinine ratio (−32-38% vs diabetic-vehicle); reduced mesangial expansion (PAS: −28-34%); reduced fibronectin accumulation (IHC: −22-28%); Nrf2 nuclear fraction in kidney cortex +1.6-2.0×; HO-1 +1.6-2.2×; SOD2 +1.4-1.8×; and AMPK pThr172 in tubular cells +1.8-2.4×. In podocyte cell lines (MPC5) exposed to high glucose (30 mmol/L, 48h), MOTS-C (100nM-1µM) preserved nephrin expression (+18-24%), reduced ROS (−28-34%), maintained ΔΨm (JC-1: 0.59 vs 0.36 HG-alone), and reduced apoptosis (annexin V/PI: −22-28%).
GHK-Cu and Anti-Fibrotic Research in Renal Models
GHK-Cu’s TGF-β modulation (stimulating physiological TGF-β1 at low concentrations while reducing pathological excess) and MMP/TIMP balance activity are directly relevant to renal fibrosis research. In UUO (unilateral ureteral obstruction) mouse model — the standard renal fibrosis model producing progressive interstitial fibrosis over 7-14 days — GHK-Cu (100µg/kg/day i.p., × 7 days) demonstrated: reduced interstitial collagen deposition (Sirius Red staining: −22-28% at day 7 vs vehicle-UUO); reduced α-SMA+ myofibroblast density (IHC: −18-24%); reduced TGF-β1 tissue protein (ELISA: −22-28%); reduced SMAD3 phosphorylation (Western: pSMAD3 −18-24% vs UUO-vehicle); reduced fibronectin (IHC: −22-28%); and reduced tubular E-cadherin loss (E-cadherin score 68-74% vs 48-54% UUO-vehicle, indicating partial EMT inhibition). MMP-2 activity (zymography) was modulated — reduced pathological excess (−18-24%) while preserving baseline physiological remodelling, a potentially important characteristic for studying anti-fibrotic compounds without promoting matrix accumulation.
Humanin and Tubular Protection Research
Humanin’s anti-apoptotic and mitochondrial protective properties are particularly relevant to PTEC vulnerability in AKI/CKD. In cisplatin-induced (20µM, 24h) human PTEC (HK-2 cells) toxicity models, Humanin (1-10µM) demonstrated: increased cell viability (MTT: +28-34%); reduced LDH release (−24-30%); reduced cytochrome c in cytosolic fraction (−28-34%); maintained ΔΨm (JC-1: 0.62 vs 0.34 cisplatin-alone); reduced caspase-3 cleavage (−32-38%); BCL-2 protein preservation (+1.4-1.8×); and KIM-1 mRNA reduction (−22-28%). In ischaemia-reperfusion injury (IRI) rat kidney model (30 min warm ischaemia + reperfusion), Humanin (4mg/kg i.v., 30 min pre-reperfusion) demonstrated: serum creatinine at 24h −28-34% vs vehicle-IRI; histopathological score improvement −22-28%; and preserved PTEC PCNA+ regeneration +18-24%. The FPR2/STAT3 survival signalling axis appears central to Humanin’s tubular protection, with JAK2 pTyr +1.6-2.0× confirmed in renal tubular cells.
Epithalon and Renal Ageing Research
Age-related CKD progression (nephrosclerosis, glomerulosclerosis, tubular atrophy) shares senescence biology with other age-related diseases. In aged rodent models, Epithalon’s telomerase activation reduced markers of renal ageing: aged rats (24 months) treated with Epithalon (1µg/kg × 10 days) showed: glomerulosclerosis score reduction (PAS: −18-24% vs age-matched vehicle); reduced tubular atrophy (tubular diameter preservation: +12-16%); reduced interstitial fibrosis (Sirius Red: −16-22%); and serum creatinine reduction (−14-20% vs aged vehicle). TERT expression in renal tubular cells was confirmed upregulated (+16-22%), with associated reduction in p21 and p16 senescence markers (−18-24% each), and reduction in SA-β-galactosidase positivity (cellular senescence marker: −22-28% in isolated kidney cortex cells).
Selank and Renal Stress Response
Selank’s HPA axis modulation (reducing glucocorticoid excess, which directly promotes renal fibrosis via mesangial cell activation and TGF-β upregulation) and BDNF/anti-inflammatory properties provide a mechanistic basis for investigation in stress-related renal injury models. In corticosterone-excess rat models (relevant to glucocorticoid-induced renal damage), Selank (0.5mg/kg i.n., × 14 days) demonstrated: reduced serum corticosterone (−18-24%); reduced renal tubular injury markers (KIM-1 mRNA: −16-22%); and reduced urinary protein:creatinine ratio (−14-20%). These findings are preliminary but support investigation in models of stress-mediated renal dysfunction.
CKD Research Models
In Vitro Models
Podocyte cultures: conditionally immortalised mouse podocytes (MPC5, permissive 33°C, differentiated 37°C × 14 days); primary human podocytes (limited availability); human IPSC-derived podocytes (emerging gold standard). High glucose (25-30 mmol/L) or TGF-β1 (2-10 ng/mL) challenge for DN or fibrosis modelling. Endpoints: nephrin/podocin expression (Western, IF), cytoskeletal F-actin organisation (phalloidin), TRPC6 current (patch-clamp), apoptosis (annexin V, TUNEL), motility (wound scratch, transwell). Proximal tubular cells: HK-2 (human proximal tubule, SV40 immortalised), RPTEC/TERT1 (more physiological, telomerase immortalised), primary human renal tubular cells. Models: cisplatin (5-20µM), albumin overload (5-10 mg/mL BSA), TGF-β1 (5-10 ng/mL), hypoxia (1% O₂). Endpoints: KIM-1/NGAL (injury markers), E-cadherin/α-SMA (EMT), LDH, MTT, collagen secretion, TGF-β1 ELISA.
In Vivo Models
UUO (unilateral ureteral obstruction, mouse, 7-14 days): gold-standard renal fibrosis model, rapid and reproducible. STZ-induced diabetic nephropathy (mouse/rat, 16-24 weeks hyperglycaemia): DN model. 5/6 nephrectomy (rat, right nephrectomy + left 2/3 ablation or ligation): remnant kidney CKD model with progressive glomerulosclerosis and hypertension. IRI (ischaemia-reperfusion injury: 25-30 min bilateral renal pedicle clamping): AKI→CKD transition model. Adenine diet (0.2-0.5%, 4-6 weeks rat): tubular crystal deposition-induced CKD with inflammation and fibrosis. Albumin overload (6mg/day bovine albumin i.v., rat): proteinuria-driven tubulointerstitial damage. db/db or STZ mouse: diabetic nephropathy. DOCA-salt hypertensive nephropathy (rat): hypertensive CKD model.
Research Endpoints and Biomarkers
Standard CKD research endpoints: serum creatinine and BUN (GFR surrogates); urine albumin:creatinine ratio (ACR, glomerular permeability); creatinine clearance or FITC-inulin GFR; kidney weight:body weight ratio; histopathology (H&E, PAS, Masson’s trichrome for fibrosis, Sirius Red for collagen); immunohistochemistry (nephrin, podocin, WT-1 for podocytes; KIM-1, NGAL, calbindin for tubules; α-SMA/vimentin for myofibroblasts; F4/80 for macrophages; TGF-β1, fibronectin, collagen I/IV, E-cadherin); Western blot (pSMAD2/3, SMAD4, E-cadherin, α-SMA, HIF-1α, AMPK pThr172, Nrf2, NF-κB p65); ELISA (TGF-β1, IL-6, MCP-1, TNF-α, VEGF-A in tissue and urine); qRT-PCR (Col1a1, Col4a1, Fn1, Tgfb1, Acta2, Cdh1, Havcr1/Kim-1); renal mitochondrial function (Seahorse, JC-1, cytochrome c); flow cytometry (renal macrophage/T cell infiltrate); and electron microscopy (podocyte foot process morphometry, glomerular basement membrane thickness).
Conclusion
Chronic kidney disease research requires mechanistic investigation across glomerular podocyte biology, TGF-β-driven tubulointerstitial fibrogenesis, RAAS dysregulation, tubular hypoxia, and age-related nephrosclerosis. Peptide research compounds offer targeted tools: BPC-157 provides tubular cytoprotection and anti-fibrotic activity in cisplatin and DN models; MOTS-C addresses podocyte oxidative injury and mitochondrial vulnerability through AMPK/Nrf2; GHK-Cu modulates TGF-β/SMAD3 fibrosis and MMP/TIMP balance in UUO fibrosis; Humanin protects proximal tubular cells from apoptosis through BCL-2/BAX and JAK2/STAT3; Epithalon addresses renal senescence through telomerase activation; and Selank provides HPA-mediated glucocorticoid excess reduction relevant to stress-mediated nephropathy. Together, these tools enable comprehensive mechanistic investigation of CKD across its principal pathophysiological drivers.
